Unlock instant, AI-driven research and patent intelligence for your innovation.

Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

A pyridyl, compound technology, applied in the directions of antiviral agents, drug delivery, aerosol delivery, etc., can solve problems such as insertion errors of subnucleotides

Active Publication Date: 2019-12-31
共晶制药公司
View PDF53 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Also, due to the absence of RNA correction enzymes, the RNA-dependent RNA polymerase of influenza vRNA produces approximately one nucleotide insertion error for every ten thousand nucleotides (which is the approximate length of influenza vRNA)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
  • Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
  • Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0438] Example 1: Side chain preparation

[0439] Some of the compounds described herein contain relatively long side chain moieties. The synthesis of precursors to some of these side chains is shown below.

[0440] sidechain-1

[0441] 2-(2-(2-Ethoxyethoxy)ethoxy)acetic acid (side chain-1)

[0442]

[0443] To a stirred solution of 2-(2-ethoxyethoxy)ethan-1-ol 1 (2.68 g, 20 mmol) in 1,4-dioxane (60 mL) was added NaOH (1.2 g , 30mmol). The mixture was stirred at room temperature for 15 minutes. After cooling to 0 °C, tert-butyl 2-bromoacetate 2 (7.8 g, 40 mmol) and 18-crown ether (250 mg) were added to the reaction mixture and stirred at room temperature for 16 h. After the starting material was consumed, the mixture was diluted with ice water (200 mL) and extracted with diethyl ether (2 x 100 mL). The separated aqueous layer was acidified (pH~2) with concentrated HCl (30 mL) and extracted with dichloromethane (2 x 250 mL). The organic layer was washed with water (2 ...

example 2

[0780] Example 2: Compound Preparation

[0781] Representative examples of the synthesis of some of the compounds described herein, as well as intermediates used to prepare these compounds, are shown below. Certain terms used in the reaction schemes presented below are defined as follows: SFC = preparative supercritical fluid chiral separation; Borsm = intermediate-013 based on recovered starting material

[0782]

[0783] 5-Fluoro-3-iodopyridin-2-amine (2)

[0784]

[0785] To 5-fluoropyridin-2-amine (1) (10g, 89.28mmol) in 2M H at 0°C 2 SO 4 To a stirred solution in aqueous solution (150 mL) was added sodium metaperiodate (7.5 g, 35 mmol) and heated at 100 °C. Then, an aqueous solution (30 mL) of sodium iodide (13.5 g, 89.28 mmol) was added dropwise at the same temperature for 3 h. After the starting material was consumed, the mixture was poured into ice water (300 mL) and washed with solid NaHCO 3 Basified (pH~8) and extracted with ethyl acetate (2 x 500 mL). Th...

example 3

[0995] Example 3: Data on selected compounds

[0996] As can be seen below, many of the compounds described herein exhibit positive effects on the survival of A / PR / 8 / 34 infected cells and inhibitory effects on the replication of A / PR / 8 / 34 influenza virus.

[0997] In vitro antiviral assay

[0998] Influenza Antiviral Test:

[0999] Inhibition of virus-induced cytopathic effect (CPE) was measured by XTT dye reduction and MDCK cells (female cocker spaniel kidney epithelial cells, ATCC CCL-34) in influenza A (strain A / PR / 8 / 34, ATCC VR-95) or influenza B (for cell cultures of strain B / Lee / 40, ATCC VR-1535) replication (Appleyard et al., Journal of Antimicrobial Chemotherapy 1(4 Suppl. ): 49-53,1975 (J AntimicrobChemother.1 (4Suppl): 49-53,1975) " and Shigeta et al's "Antimicrob Agents Chemotherapy 41 (7): 1423-1427, 1997 (Antimicrob Agents Chemother.41 (7):1423-1427, 1997) "). Use Dulbecco's minimal essential medium supplemented with 10% heat-inactivated fetal bovine serum (FB...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
densityaaaaaaaaaa
Login to View More

Abstract

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas l-lll, or a pharmaceutically acceptable salt thereof.A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Description

technical field [0001] The present invention relates generally to inhibitors of influenza virus replication, and methods of treating or preventing influenza infection by administering said inhibitors to a patient in need of such treatment. Background technique [0002] Influenza spreads around the world in seasonal epidemics, killing hundreds of thousands of people each year and millions in pandemic years. For example, the 20th century saw three influenza pandemics that killed tens of millions of people, each of which was caused by the emergence of a new strain of a human virus. Typically, these new strains arise as a result of the spread of existing influenza viruses from other animal species to humans. [0003] Influenza is spread primarily from person to person through larger virus-carrying droplets produced when an infected individual coughs or sneezes; these larger droplets may then settle in close proximity (eg, within about 6 inches) of the infected individual On th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D519/00A61P31/16A61K31/519
CPCA61P31/16C07D519/00A61K9/0073A61K9/127A61K9/14A61K9/0019A61K31/519A61K45/06
Inventor 伊里娜·C·雅各布森迈克尔·大卫·费思塞姆·斯科·李
Owner 共晶制药公司